ABCD nationwide oral semaglutide audit launched at ADA 2021
ABCD launched its nationwide oral semaglutide audit earlier this week.
The clinical trials with semaglutide suggest that it may be more effective than the other GLP-1 receptor agonists.
Results from the ABCD semaglutide audit, presented this week at ADA 2021, have demonstrated significant reductions in HbA1c and weight following commencement of semaglutide in a real-world cohort that was heavier with higher baseline HbA1c levels than those in clinical trials.
Most interestingly, further reductions in HbA1c and weight occurred when switching from another GLP1-RA to semaglutide, although somewhat attenuated compared to the GLP1-RA naïve group.
Clinical trials with oral semaglutide suggest that it is also very effective compared to other available diabetes medications both in reducing HbA1c and weight.
ABCD will now explore the extent to which the experience in clinical trials translates into the real world in its upcoming audit.
Attendees will have access to the online tool which will allow them to analyse the data of their own patients for their own local interests.
At the same time the data will automatically be available for national analysis of anonymised date.
Contributors will be acknowledged in all papers and presentations from the audit data and biggest contributors will be offered the possibility of being co-authors.
To register for the audit, click here.